Clenbuterol

> **Note:** This entry covers both "Clenbuterol" (Product #11) and "Clen" (Product #14) in the catalog, which are the same compound at the same concentration and price.

Clenbuterol Hydrochloride is a sympathomimetic amine classified as a beta-2 adrenergic receptor agonist. It is not an anabolic steroid. Originally developed as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease (COPD), Clenbuterol gained widespread use in body composition research due to its potent thermogenic and anti-catabolic properties. It is approved for human therapeutic use in several European and Latin American countries, though not by the FDA in the United States (where albuterol is preferred).

Clenbuterol's mechanism of action centers on beta-2 adrenoceptor stimulation. When Clenbuterol binds these receptors in adipose tissue, it initiates a signaling cascade (cAMP → protein kinase A → hormone-sensitive lipase activation) that directly stimulates lipolysis — the breakdown of stored triglycerides into free fatty acids and glycerol for use as metabolic fuel. Simultaneously, it increases basal metabolic rate by elevating core body temperature (thermogenesis) by approximately 0.5–1.0°F. Clenbuterol also exhibits significant anti-catabolic effects: it reduces the rate of protein degradation in skeletal muscle, making it a valuable adjunct during caloric deficit phases where muscle preservation is a priority.

In research applications, Clenbuterol accelerates fat loss beyond what dietary restriction and exercise alone can achieve. It is a cornerstone of cutting and pre-contest protocols, frequently stacked with T3 (Cytomel), anabolic steroids (Anavar, Winstrol, Trenbolone), and/or Cardarine. The compound's effects on resting energy expenditure are measurable and dose-dependent — researchers typically report a 5–10% increase in daily caloric expenditure at moderate dosages.

Clenbuterol is suitable for intermediate and advanced researchers. While it is not an anabolic steroid and does not suppress the HPTA, its cardiovascular stimulant effects require respect. Researchers with pre-existing cardiac conditions, hypertension, or anxiety disorders should exercise caution. It is appropriate for both male and female researchers.

Clenbuterol has a long half-life of approximately 36–48 hours, which means blood levels accumulate with consecutive daily dosing. This pharmacokinetic profile necessitates an escalating dosing approach: researchers typically begin at 20–40 mcg daily and increase by 20 mcg every 2–3 days until reaching a maximum of 100–140 mcg daily. The most common administration pattern is a 2-weeks-on, 2-weeks-off cycle to manage beta-2 receptor downregulation (though some researchers use Ketotifen at 2 mg nightly to upregulate receptors and run continuous protocols). Side effects are sympathomimetic in nature: tremors (particularly in the hands), elevated heart rate, insomnia, and muscle cramps (addressed with taurine supplementation at 3–5 g daily and adequate potassium intake). Cardiac monitoring is prudent during administration.